Safety evaluation of medical devices: US food and drug administration and international standards organization guidelines

International Journal of Toxicology

Volumn 18, Issue 4, 1999, Pages 275-283

  Northup, Sharon J ^a,b  

^a Northup Regulatory Toxicol Services   (United States)

^b Northup Regulatory Toxicol Services   (United States)

Author keywords

Bioassays; Biocompatibility; Medical Devices; Safety; Toxicity

Indexed keywords

BIOCOMPATIBILITY; BLOOD COMPATIBILITY; CONFERENCE PAPER; DEVICE; EYE IRRITATION; GENOTOXICITY; MEDICAL INSTRUMENTATION; PRACTICE GUIDELINE; RABBIT; SAFETY; STANDARDIZATION; TOXICITY TESTING;

ORYCTOLAGUS CUNICULUS;

EID: 0032856508     PISSN: 10915818     EISSN: None     Source Type: Journal    
DOI: 10.1080/109158199225431     Document Type: Conference Paper

References (15)

1. Anonymous. 1995a. Guidelines for basic biological tests of medical materials and devices (Japan). Tokyo, Japan: National Institute of Health Sciences.
2. Anonymous. 1995b. Protein hydrolysate injection. US Pharmacopeia 23:1337-1338.
3. Anonymous. 1996. AAMI standards and recommended practices. Vol. 4: Biological evaluation of medical devices. Arlington, VA. Association for the Advancement of Medical Instrumentation.
4. ASTM. 1995. F 748-95 Standard practice for selecting generic biological test methods for materials and devices. Annual book of ASTM standards, section 13, medical devices and services, 193-197. West Conshohocken, PA: ASTM.
5. Center for Devices and Radiological Health, US FDA. 1987. Tripartite biocompatibility guidance for medical devices. Blue Book Memorandum G87-1. Rockville, MD: US Food and Drug Administration (Available from: http:/www.fda.gov/cdrh/g87-1.html).
6. Center for Devices and Radiological Health, US FDA. 1995. Required biocompatibility training and toxicology profiles for evaluation of medical devices. Blue Book Memorandum G95-1. Rockville, MD: US Food and Drug Administration (Available from: http:/fda.gov/cdrh/g951.html).
7. Grasso, P., M. Sharratt, and A. J. Cohen. 1991. Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Ann. Rev. Pharmacol. Toxicol. 31:253-287.
8. OECD Guidelines for testing of chemicals. Part 451: Carcinogenicity studies. Geneva, Switzerland: Organization for Economic Cooperation and Development.
9. OECD Guidelines for testing of chemicals. Part 453: Combined chronic toxicity/carcinogenicity studies. Geneva, Switzerland: Organization for Economic Cooperation and Development.
10. OECD Guidelines for testing of chemicals. Part 471: Genetic toxicology: salmonella typhimurium, reverse mutation assay. Geneva, Switzerland: Organization for Economic Cooperation and Development.
11. OECD Guidelines for testing of chemicals. Part 473: Genetic toxicology: In vitro mammalian cytogenetic test. Geneva, Switzerland: Organization for Economic Cooperation and Development.
12. OECD Guidelines for testing of chemicals. Part 479: Genetic toxicology: In vitro sister chromatid exchange assay in mammalian cells. Geneva, Switzerland: Organization for Economic Cooperation and Development.
13. US Food and Drug Administration. 1998. FDA Modernization Act of 1997: Guidance for the recognition and use of consensus standards. Fed. Register 63:9561-9570.
14. USP. Subcommittee on In vitro Toxicity. 1989. Application of the concept of biological reactivity to compendial tests. Pharmacopeial Forum 15:4804-4811.
15. Woodward, S. C., and T. N. Salthouse. 1986. The tissue response to implants and its evaluation by light microscopy. In Handbook of biomaterials evaluation, ed. A. F. von Recum, 364-378. New York: MacMillan.